Bayer’s “challenging year” persisting
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
What is proving to be a “challenging year” for Bayer Consumer Health has continued into the second quarter of 2018, according to the German group’s chief executive officer Werner Baumann.
You may also be interested in...
Bayer Consumer Chief Identifies 'Root Causes' Of Slump, Initiates Growth 'Fix'
Bayer's Consumer Health chief Heiko Schipper hopes a focus on innovation and a leaner portfolio will help return business to mid-single-digit growth by 2022. German firm has identified North American business as the "key area to fix."
Bayer's Consumer Chief Initiates Turnaround Plan In Bid To Return Troubled Business To Growth
Bayer's Consumer Health chief Heiko Schipper is hoping a focus on innovation and a leaner portfolio will help return the business to mid-single-digit growth by 2022. The German firm has identified its North American business as the 'key area to fix'.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.